TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05049642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
Study: NCT05321589

Intervention type: OTHER
Group type: OTHER
Intervention: impression techniques for implant used for maxillary screw retained hybrid prosthesis
Description: conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done

Intervention type: OTHER
Group type: OTHER
Intervention: impression techniques for implant used for maxillary screw retained hybrid prosthesis
Description: conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done
Study: NCT05859581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Beyond complete mesocolic excision surgery
Description: If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
Study: NCT06451094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR
Description: Transfer Energy Capacitative and Resistive Therapy
Study: NCT05686811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release therapy therapy
Description: Group A was treated with myofascial release therapy and routine physical therapy. For routine physical therapy subjects will first applied TENS, hot pack and neck isometric exercises then myofascial release therapy will be given. For myofascial release therapy subjects was in the supine or possibly sitting position, the examiner was seated at the head of the table, the examiner was used his right thumb to palpate (using flat palpation) the upper trapezius muscles from medial to lateral to establish if any MTrPs are present. The entire mass of the upper trapezius muscle is lifted by the supraspinatus muscle and grasped with a pincer grasp. The muscles at this point rotate between the thumb and forefinger to detect the delicate location of the trigger point. Treatment session longs for 10 minutes of myofascial release on each side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation technique
Description: This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
Study: NCT04644081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP
Description: LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
Study: NCT06455423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Manipulation
Description: Thoracic manipulation will be administered at hypomobile or stiff segments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Manipulation
Description: Thoracic manipulation will be administered at hypomobile or stiff segments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chin tuck in exercises
Description: Chin tuck in exercises
Study: NCT04644081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaCBT
Description: CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
Study: NCT06505317

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-based PAD screening intervention
Description: Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-based PAD screening intervention
Description: Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI-based PAD screening intervention
Description: Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis.
Study: NCT05613595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychotherapy
Description: Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling Group
Description: Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
Study: NCT04881175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Treatment
Description: Single-arm group using the FlexSure Applicator device.
Study: NCT06513975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART BP
Description: A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sphygmomanometer
Description: Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
Study: NCT06140732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab and apatinib
Description: camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
Study: NCT04664270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: e-CBT + Mindfulness + Problem Solving
Study: NCT04554108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic strategy
Description: Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic strategy
Description: Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
Study: NCT06321952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA robotic assist TKA
Description: total knee replacement with ROSA robotic assist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iassist TKA
Description: total knee replacement with iassist
Study: NCT06226948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Participants will wear CGM monitors for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Participants will wear CGM monitors for 10 days.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visualization
Description: Enriched visualization of SCORE2 CVD risk.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visualization
Description: Enriched visualization of SCORE2 CVD risk.
Study: NCT06632483

Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Prescibed as per local label
Study: NCT04647253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGENT DCB
Description: Drug coated PTCA balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA balloon catheter
Description: PTCA balloon catheter
Study: NCT06705192

Intervention type: DRUG
Group type: OTHER
Intervention: VES001
Description: VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg.
Study: NCT06709521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol,N,N´ -Bis(2,3-dihydroxypropyl)-5-\[N-(2,3-dihydroxypropyl)-acetamido\]-2,4,6-triiodoisophthalamide, is a non-ionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 (iodine content 46.36%)
Study: NCT06709781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the heat while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (no cooling modalities)
Description: Subjects will exercise for 60 minutes in the heat while being exposed to no cooling modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the heat while being exposed to a combination of skin wetting and a fan. The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout. Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Spray and Fan
Description: Subjects will exercise for 60 minutes in the heat while being exposed to a combination of skin wetting and a fan. The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout. Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
Study: NCT06707688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amulet™ 2 Left Atrial Appendage (LAA) Occluder
Description: Patient will undergo the implantation of the Amulet™ 2 Left Atrial Appendage (LAA) Occluder
Study: NCT06057402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
Study: NCT06719544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enlicitide
Description: Oral tablet
Study: NCT06703606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MARSTACIMAB
Description: Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
Study: NCT06715709

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone IV
Description: Patients will receive dexamethasone administered intraoperatively at the time of anesthesia. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV+Oral
Description: Patients will receive dexamethasone administered intraoperatively and on the morning of the first postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV+Oral 2 Day
Description: Patients will receive dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
Study: NCT06723665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: 18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: 18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
Study: NCT05839730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker PLR + TRT ON
Description: RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
Description: RAMware modified implantable pulse generator (IPG)
Study: NCT06709820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4060874
Description: Administered SC
Study: NCT05236283

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Culture
Description: Blood Culture

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Culture
Description: Blood Culture
Study: NCT06709820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4060874
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4060874
Description: Administered SC
Study: NCT06429579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy
Description: Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Only conventional drug therapy
Description: Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
Study: NCT06709820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4060874
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4060874
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT06721962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRX103
Description: TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose cyclophosphamide conditioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose cyclophosphamide conditioning.
Study: NCT06733285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensodyne Rapid Relief
Description: Toothpaste containing 0.454 % weight/weight (w/w) SnF2 (1100 parts per million \[ppm\] fluoride).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection
Description: A regular fluoride toothpaste containing 1000 ppm fluoride.
Study: NCT06735976

Intervention type: DEVICE
Group type: OTHER
Intervention: PAVM Embolization
Description: This study consists of one group. All participants will undergo PAVM embolization with a LOBO™ device.

Intervention type: DEVICE
Group type: OTHER
Intervention: PAVM Embolization with a LOBO™ device
Description: Participants will undergo PAVM embolization with the LOBO™ device per standard of care.
Study: NCT06739122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study: NCT06735638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OTC MIE Esophagectomy
Description: Consenting patients will undergo minimally invasive esophagectomy (MIE) using the Out of the Cage (OTC) robotic-assisted technique. The procedure will follow the exact standard steps of traditional VATS/RATS esophagectomy, except the thoracic ports will be placed in the subcostal plane. The number of ports (1-4) will be determined based on the patient and case characteristics.~The Da Vinci Xi® surgical system will be used to perform the thoracic portion of the esophagectomy through subcostal ports using the standard technique. Once the procedure is completed, the robotic arms and ports will be removed from the chest, and figure-of-8 stitches with non-absorbable sutures will be placed to close the diaphragm at the port sites. A 24 Fr soft chest tube will be left in place, as per standard VATS/RATS esophagectomy protocols. Incisions will be closed in the standard manner.
Study: NCT06734117

Intervention type: DIAGNOSTIC_TEST
Intervention: Elecsys® Troponin T hs Gen 6
Description: It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.

Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.
Study: NCT06746064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF10073 (Part 1 - SAD)
Description: Single doses of CHF10073 for each cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1 - SAD)
Description: Single doses of placebo matching CHF10073 for each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF10073 (Part 2 - MAD)
Description: Multiple doses of CHF10073 for each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF10073 (Part 3)
Description: Single dose of CHF10073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2 - MAD)
Description: Multiple doses of placebo matching CHF10073 for each cohort